---
document_datetime: 2023-09-21 17:28:20
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/steps-after-cutoff/plavix-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf
document_name: plavix-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf
version: success
processing_time: 2.3285265
conversion_datetime: 2025-12-28 14:28:09.889131
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Steps taken after granting the Marketing Authorisation

## For procedures finalised after 1 September 2004 please refer to module 8B.

- The  Marketing  Authorisation  Holder  submitted  to  the  EMEA  on  06  November  1998  an application  for  one  type  I  variation  falling  within  the  scope  of  item  No  3  of  Annex  I  to Commission  Regulation  (EC)  No  542/95,  as  amended.  The  Marketing  Authorisation  Holder applied for:

A change in the address of the marketing authorisation holder.

On 03 December 1998, the EMEA approved the variation. The variation required amendments in the relevant sections (annexes I, IIIA and IIIB) of the Commission decision. The European Commission amended the Decision on 01 February 1999.

- The  Marketing  Authorisation  Holder  submitted  to  the  EMEA  on  29  December  1998  an application  for  one  type  I  variation  falling  within  the  scope  of  item  No  8  of  Annex  I  to Commission  Regulation  (EC)  No  542/95,  as  amended.  The  Marketing  Authorisation  Holder applied for:

A change in the qualitative composition of immediate packaging material.

On 05 February 1999, the EMEA approved the variation. This variation required amendments to annexes I and IIIB of the Commission Decision. Revised EMEA notification dated 01 April 1999  regarding  EU  numbers.  The  European  Commission  amended  the  Decision  on  11  June 1999.

- The  Marketing  Authorisation  Holder  submitted  to  the  EMEA  on  04  February  1999  an application  for  one  type  I  variation  falling  within  the  scope  of  item  No  1  of  Annex  I  to Commission  Regulation  (EC)  No  542/95,  as  amended.  The  Marketing  Authorisation  Holder applied for:

An alternative manufacturing site for the finished product.

On 22 March 1999, the EMEA approved the variation. This variation required amendments to annexes  II  and  IIIB  of  the  Commission  Decision.  The  European  Commission  amended  the Decision on 16 July 1999.

- The  Marketing  Authorisation  Holder  submitted  to  the  EMEA  on  04  February  1999  an application  for  one  type  I  variation  falling  within  the  scope  of  item  No  16  of  Annex  I  to Commission  Regulation  (EC)  No  542/95,  as  amended.  The  Marketing  Authorisation  Holder applied for:

A change in the batch size of the finished product.

On  22  March  1999,  the  EMEA  approved  the  variation.  This  variation  did  not  require  any amendment to the Commission Decision.

- The Marketing Authorisation Holder submitted to the EMEA on  08 April 1999 an application for  one  type  I  variation  falling  within  the  scope  of  item  No  32  of  Annex  I  to  Commission Regulation (EC) No 542/95, as amended. The Marketing Authorisation Holder applied for:

A new engraving on the tablets.

On 13 May 1999, the EMEA approved the variation. This variation required amendments to annexes  I  and  IIIB  of  the  Commission  Decision.  The  European  Commission  amended  the Decision on 08 July 1999.

- The Marketing Authorisation Holder submitted to the EMEA on 08 April 1999 an application for  one  type  I  variation  falling  within  the  scope  of  item  No  14  of  Annex  I  to  Commission Regulation (EC) No 542/95, as amended. The Marketing Authorisation Holder applied for:

A change in specifications of the active substance.

On  06  July  1999,  the  EMEA  approved  the  variation.  This  variation  did  not  require  any amendment to the Commission Decision.

<div style=\"page-break-after: always\"></div>

- On 26 April 1999, the Marketing Authorisation Holder submitted a Type II variation application in accordance with Article 6 of Commission Regulation (EC) No. 542/95 of 10 March 1995, as amended.  The  scope  of  the  variation  related  to  the  update  of  the  Summaries  of  Product Characteristics and Package Leaflets according to the assessment of the second PSUR

On 20 May 1999 the CPMP approved the variation. The variation required amendments in annexes I and IIIB of the Commission Decision. The European Commission amended the Decision on 07 September 1999.

- Between 31 August 1999 and 4 May 2000, the EMEA issued Notifications for the approval of five type I variations concerning
- -change in the manufacturer of the active substance,
- -change in the batch size of the active substance,
- -minor change of manufacturing process of the active substance,
- -change in the manufacturer of the active substance,
- -change  of  the  manufacturing  site  for  part  of  the  manufacturing  process  of  the  medicinal product.

These variations did not require any amendment to the Commission decision.

- On  10  February  2000,  the  Marketing  Authorisation  Holder  requested  to  update  names  and adresses of local representatives in the package leaflet, by means of a Notification under Article 10(3)  of  Directive  92/27/EEC.  Following  EMEA's  Notification  on  10  March  2000,  the European Commission amended the Decision (Annex IIIB) on 03 May 2000.
- On  07  February  2000,  the  Marketing  Authorisation  Holder  submitted  a  Type  II  variation application  in  accordance  with  Article  6  of  Commission  Regulation  (EC)  No.  542/95  of  10 March 1995, as amended. The scope of the variation related to the update of the Summaries of Product Characteristics according to the assessment of the fourth PSUR. On 12 April 2000 the CPMP approved the variation. At the same time, annex II of the Commission Decision has been updated. The variation required amendments in annexes I and II of the Commission Decision. The European Commission amended the Decision on 13 July 2000.
- On 15 May 2000, the Marketing Authorisation Holder submitted a Type II variation application in accordance with Article 6 of Commission Regulation (EC) No. 542/95 of 10 March 1995, as amended. The Marketing Authorisation Holder applied for a new formulation of the film-coated tablet containing a new polymorphic form of the active substance. In addition to the subsequent changes in the SPC, Labelling and PL, these annexes have been revised according to the latest templates.  On  21  September  2000  the  CPMP  approved  the  variation.  The  variation  required amendments  in  annexes  I,  IIIA  and  IIIB  of  the  Commission  Decision.  The  European Commission amended the Decision on 15 January 2001.
- On  26  July  2000,  the  Marketing  Authorisation  Holder  requested  to  introduce  changes  to  an aspect of the labelling not connected to the Summary of Product Characteristics, by means of a Notification under Article 10(3) of Directive 92/27/EEC. Following EMEA's Notification on 1 August 2000, the European Commission amended the Decision (Annex IIIA) on 25 September 2000.
- On  5  September  2000,  the  Marketing  Authorisation  Holder  submitted  a  Type  II  variation application  in  accordance  with  Article  6  of  Commission  Regulation  (EC)  No.  542/95  of  10 March 1995, as amended. The Marketing Authorisation Holder applied for an update of the SPC following the assessment of a PSUR. On 16 November 2000 the CPMP approved the variation. The  variation  required  amendments  in  annexes  I  and  IIIB  of  the  Commission  Decision.  The European Commission amended the Decision on 13 March 2001.

<div style=\"page-break-after: always\"></div>

Subsequent post Marketing Authorisation applications agreed upon are summarised in the table below:

| Scope                                                                                                                                                      | Application number   | Type of modification 1   | Notification/ Opinion issued on 2   | Commission Decision Issued/amended on   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|--------------------------|-------------------------------------|-----------------------------------------|
| Update of Summary of Product Characteristics (sections 4.4, 4.5 and 4.8) andPackage Leaflet following the assessment of the 5 th PSUR.                     | II/18                | II                       | 29.03.01                            | 16.07.01                                |
| Batch size of active substance                                                                                                                             | I/19                 | I                        | 04.03.01                            | N/A                                     |
| Minor change of manufacturing process of the active substance                                                                                              | I/20                 | I                        | 04.03.01                            | N/A                                     |
| Change in or addition of manufacturer(s) of active substance                                                                                               | I/21                 | I                        | 19.07.01                            | N/A                                     |
| Update of the Summary of Product Characteristics and Package Leaflet                                                                                       | II/22                | II                       | 23.08.01                            | 28.01.02                                |
| Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                           | N/23                 | N                        | 08.10.01                            | 17.12.01                                |
| Additional indication (Acute Coronary Syndrome)                                                                                                            | II/24                | II                       | 28.05.02                            | 09.09.02                                |
| Change following modification(s) of the manufacturing authorisation                                                                                        | I/25                 | I                        | 13.12.01                            | 19.02.02                                |
| Change in or addition of manufacturing site(s) for part or all of the manufacturing process                                                                | I/26                 | I                        | 16.05.02                            | 19.06.02                                |
| Change in the name of a manufacturer of the medicinal product                                                                                              | I/27                 | I                        | 27.05.02                            | 27.05.02                                |
| Extension of shelf-life as foreseen at time of authorisation                                                                                               | I/28                 | I                        | 20.12.02                            | 03.02.03                                |
| Change in test procedure for starting material/intermediate used in manuf. of active substance                                                             | I/29                 | I                        | 19.02.03                            | 03.03.03                                |
| Batch size of active substance                                                                                                                             | I/30                 | I                        | 10.01.03                            | 16.01.03                                |
| Change in the batch size of finished product                                                                                                               | I/31                 | I                        | 27.03.03                            | 01.04.03                                |
| Minor changes in manufacture of the medicinal product                                                                                                      | I/32                 | I                        | 27.03.03                            | 01.04.03                                |
| Change in pack size for a medicinal product                                                                                                                | I/33                 | I                        | 14.02.03                            | 24.03.03                                |
| Change in pack size for a medicinal product                                                                                                                | I/34                 | I                        | 14.02.03                            | 24.03.03                                |
| Renewal                                                                                                                                                    | R/35                 | R                        | 22.05.03                            | 08.10.03                                |
| Change(s) to the manufacturing process for the active substance                                                                                            | II/36                | II                       | 25.09.03                            | 02.10.03                                |
| Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                           | N/37                 | N                        | 20.11.03                            | 22.12.03                                |
| Update of Summary of Product Characteristics and Package Leaflet                                                                                           | II/38                | II                       | 03.06.04                            | 02.08.04                                |
| Replacement/add. of manufacturing site: Secondary packaging site and change in BR/QC testing - repl./add. manuf. responsible for BR - not incl. BC/testing | IA/39                | IA                       | 11.06.04                            | -                                       |